Circulating tumour DNA in early stage colorectal cancer: can blood tell all?
作者信息
To Yat Hang, Lee Margaret, Gibbs Peter, Tie Jeanne
机构信息
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Division of Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S358. doi: 10.21037/atm.2019.09.55.
Abstract
摘要
相似文献
1
Circulating tumour DNA in early stage colorectal cancer: can blood tell all?早期结直肠癌中的循环肿瘤DNA：血液能说明一切吗？
Ann Transl Med. 2019 Dec;7(Suppl 8):S358. doi: 10.21037/atm.2019.09.55.
2
Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study.新型 DNA 甲基化生物标志物具有高灵敏度和特异性，可用于基于血液的结直肠癌检测——一项临床生物标志物发现和验证研究。
Clin Epigenetics. 2019 Nov 14;11(1):158. doi: 10.1186/s13148-019-0757-3.
3
Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.检测循环肿瘤细胞作为监测结直肠癌患者姑息化疗的潜在替代标志物。
J Exp Clin Cancer Res. 2004 Dec;23(4):633-9.
4
Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer.循环肿瘤细胞和循环游离核酸作为结直肠癌的预后和预测生物标志物。
Cancer Lett. 2014 Apr 28;346(1):24-33. doi: 10.1016/j.canlet.2013.12.019. Epub 2013 Dec 22.
5
Circulating tumour cells and circulating nucleic acids as a measure of tumour dissemination in non-metastatic colorectal cancer surgery.循环肿瘤细胞和循环核酸作为非转移性结直肠癌手术中肿瘤播散的一种衡量指标
Eur J Surg Oncol. 2015 Mar;41(3):309-14. doi: 10.1016/j.ejso.2014.12.005. Epub 2014 Dec 30.
6
Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.结直肠癌转化整合的临床相关结局评估与生物标志物分析（ACROBATICC）：一项基于人群的连续队列研究方案，纳入接受手术治疗的结直肠癌和切除的结直肠肝转移患者
J Transl Med. 2016 Jun 29;14(1):192. doi: 10.1186/s12967-016-0951-4.
7
Circulating tumour cell RNA characterisation from colorectal cancer patient blood after inertial microfluidic enrichment.
MethodsX. 2019 Jun 17;6:1512-1520. doi: 10.1016/j.mex.2019.06.012. eCollection 2019.
8
[Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].[结直肠癌的液体活检：肿瘤诊断中循环肿瘤DNA分析概述]
Pathologe. 2019 Dec;40(Suppl 3):244-251. doi: 10.1007/s00292-019-00698-3.
9
[Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].[循环髓系抑制细胞及其在肿瘤免疫学中的作用]
Klin Onkol. 2017 Spring;30(Supplementum1):166-169.
10
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.在肿瘤发生过程中，血管内皮生长因子（VEGF）的蛋白质表达模式从可溶性异构体转变为细胞相关异构体。
BMC Cancer. 2005 Oct 4;5:128. doi: 10.1186/1471-2407-5-128.
本文引用的文献
1
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.I至III期结直肠癌患者血浆游离DNA的深度测序分析
JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528.
2
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.循环肿瘤DNA检测在非转移性结直肠癌术后监测中的预后潜力
JAMA Oncol. 2019 Aug 1;5(8):1118-1123. doi: 10.1001/jamaoncol.2019.0512.
3
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).利用循环肿瘤 DNA（ctDNA）检测实体瘤分子残留疾病（MRD）。
Mol Diagn Ther. 2019 Jun;23(3):311-331. doi: 10.1007/s40291-019-00390-5.
4
Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.循环肿瘤 DNA 监测结直肠癌：一项前瞻性队列研究，评估与组织甲基化、癌症特征和手术切除的关系。
Clin Epigenetics. 2018 May 16;10:63. doi: 10.1186/s13148-018-0500-5. eCollection 2018.
5
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.III期结肠癌辅助化疗的疗程
N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.
6
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.在转移性结直肠癌患者的循环肿瘤 DNA 中进行 RAS 突变分析：AGEO RASANC 前瞻性多中心研究。
Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.
7
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.多模态治疗局部晚期直肠癌过程中的循环肿瘤 DNA 连续分析：一项前瞻性生物标志物研究。
Gut. 2019 Apr;68(4):663-671. doi: 10.1136/gutjnl-2017-315852. Epub 2018 Feb 2.
8
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.血浆循环肿瘤DNA RAS突变分析在转移性结直肠癌患者诊断及治疗监测中的应用
Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.
9
Clinical and molecular assessment of regorafenib monotherapy.瑞戈非尼单药治疗的临床及分子评估
Oncol Rep. 2017 Apr;37(4):2506-2512. doi: 10.3892/or.2017.5456. Epub 2017 Feb 15.
10
Liquid biopsies come of age: towards implementation of circulating tumour DNA.液体活检时代的到来：迈向循环肿瘤 DNA 的临床应用。
Nat Rev Cancer. 2017 Apr;17(4):223-238. doi: 10.1038/nrc.2017.7. Epub 2017 Feb 24.
Zotero 插件